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To assess thc cfficacy of an ;11 11;.10 adcnoviral-mcdi-
atcd cyt:ot:oxic gcnc thcrapy, hUluan luclanomas wcrc I established in nudc micc and transduccd with hcrpcs 
simplex virus-thymidinc kinasc (tk) followcd by 
treatment: with ganciclovir (GCV). In initial cxpcri-
ments, adcnovirus (adv) containing thc /3-galactosi-
dasc reportcr gcnc was cmploycd to dctcrnlinc mcl-I anoma cell infcctivity ill IIitl'o. In cOluparison to 
. murine mclanoma cclllincs B16 and Kl735-M2, hu-I man A3 75-SM cclls cxhibited up to a 10-fold grcatcr 
susceptibilit:y to adenoviral transduction, similar to 
the degree of infectivity found for human cpidermal 
HaCaT cells. In addition, human A375-SM mclanoma 
I cells exhibited a greatcr sensitivity ill IIit.,O to the , cytotoxic effccts of transduction with tk-adv and I treatment: with GCV, which was mcdiatcd by a strong 
bystander effect. III. IIillO, intratunloral injcction of 
relatively largc human melanomas (160 mm3) with 1.2 
M clanoma is one of the m ost m orbid of human , can cers, beca use of its propensity for me tastases I and res istance to con ventional tl'eatment (Fid ler, 1992; J ohnson ct al. 1995). W hIle ea rly locahzed disease can be cured by surgical excision, once 
1 the rapid vertical growth phase gives rise to distan t metastases, 
lurgery, c h e m otherapy, and radiotherapy ha ve onl y a generally 
I rransient efficacy Oohmon ct aI, 1995). Indeed , fo r late disease (stage 4 ), no curative therapy exi sts. Given the ala rllling in crease in 
, the incide n cc of mclanoma in caucasians over the past 50 yea rs, 
predic tions suggest that, in the United States alone, up to one in 75 
individuals w ill develo p cutaneous melanoma b)' the yea r 2000 
(Rigel er nl, 1987 ; Kigcl, 1992). T his fa ct, coupled w ith the 
pred iction that ozone depletion is like ly to increase the overall 
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X 109 pfu oftk-adv, followed by intraperitoneal GCV 
trcatmcnt (60 mg/kg twice daily) over 4 days, typi-
cally rcsulted in a 50'!.) reduction in mclanoma growth 
rate conlparcd to mock or untrcatcd controls. More-
over, histomctrical analysis cmploying a rigorous 
cOluputcrized imaging systelu revealed that the re-
sidual viablc tumor area in thc tk-adv/GCV -treated 
group was only onc-fifth that of solvcnt controls. 
Thcsc data show that adv is a highly cfficicnt in IIillo 
genc delivery systcm to trcat cxperimental human 
melanomas. In comparison to a prcvious murinc 
melanolua study, human mclanonlas appeared to 
exhibit a greater sensitivit:y to this cytotoxic trcat-
ment ill .lillO, which may hold significant promisc for 
dcvclopmcnt of cffectivc gcne thcrapy luodalitics to 
trcat luelan0J.11a in humans. K ey 1V0"ds: ca,,,cel'/gelle 
tll erapyladellollil'lls/II"de mice. ] I,,"est Del'llratoi 106: 1163-
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tum~r incidence (G lass and H oover. 1989; Gleason et aI, 1993), 
makes the development of novel. e fl:cc tivc trea tment strategies 
highly desirable . 
O ne po tentially useful strategy is the app lication of somatic cell 
gene therapy techniques that transduce tum or ce ll s with a va riety of 
immuno logic o r drug-sensitiz ing "suicide" genes (Fluiwara 1'1 aI, 
1994; Hart and Vi le, 1994; Vile and Ru ssel, 1994) . O n e example of 
the latter is transfer of the herpes simplex vi rus-thymidine kinase 
(H SV -tk) gene follow ed by admin istration of the drug ganciclovir 
(GCV). T hi s no rmally nontoxic drug, an ana log of guanosine, is 
phosphorylated by HSV-tk and converted to an interm ediate that 
inhibits DNA synthesis by ac ting as a chain terminator (Matthews 
and Boehme, 1988) that kill s dividing cells (Moolten , 1986). Thus, 
this approach is eminently suitable for the treatm ent of rapidly 
growing solid tumors that are invading no rmal tissues comprised 
largely o f quiescent ce lls (Moolten, 1986). Furthermore, by em-
ploying this particular combination , not aU tumor cells need to be 
transduced du e to the e:-..;stence of the " bystander e ff"ec t" (Freem an 
et aI, 1993), in which tumor ce ll s in proximi ty to HSV-tk-
transduced cells are also killed when phosphorylated GCV is 
released (Freeman cl aI, 1993) . 
To date, the majori ty of gene therapy treatment modalities re ly 
on an ex ";(10 approach (Crowley and Seigler, '1993; Irie and 
DeNunzio, 1993; Foa et al. 1994; Po rgador el aI, 1994; Rosenth al el 
aI, 1994; Rankin . 19(5) in wh.ich autologous o r allogeneic cells are 
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transduced by retroviral or nonviral means w ith cytokin es or ce ll 
surface signal genes assumed to be pivotal in the e licitation or 
enhanceme nt of an antitumor immune reaction. To be more useful 
in a clinical setting, however, direct delivery to tumor cells ill 11;'10 
would be advantageous. Toward this goa l, one attractive method 
involves the use of recombinant, replication-defective aden ovirus 
(adv) (Chen CI ai, 1994), w hic h can be produced at high titers, w ith 
the added safety feature of there being li ttle significant potential for 
integration o r insertional mutagenesis (Kozarsky and Wilson, 
1993). Previously, adv-mediated gen e delivery was used to su ccess-
fu ll y treat estab li sh ed murine melanomas with this suicide HSV-
tk/GCV gene therapy approach (Bonnekoh cf ai, 1995) . During the 
course of these experiments, we observed that murine B16 mela-
noma cell s were relatively resistant to adv infectivity, which may 
have contributed to the continued tumor growth in treated groups 
(Bonnekoh e/ ai, 1995). To assess w heth e r this was a property of 
melanoma cell s in genera l or restricted to murine ce ll s and to 
determine whether t hi s delivery system wou ld b e an effective 
treatment modality for experimental human melanomas, we now 
report that the human melanoma cell line A375-SM was 10-fold 
more susceptible to adv infection than murine cell s ill IIi/rD. 111 lIivo 
human melanoma growth rate was reduced by 50% after HSV-tk 
delivery and treatment of animals with GCV, and moreover, the 
residual viable tumor area was found to be significantly reduced to 
20% of that of controls. 
MATERIALS AND METHODS 
Cell Lines The human A375-SM, the murine K1735-M2 and B16 
melanoma cell lines were provided by Dr. I. J. Fidler (M. D. Anderson 
Cance r Center, The University of Texas, Houston) (Fidler, 1975; Koz-
lowski el ai, 1984: Starosels)..--y el ai, 1991) , and the human HaCaT 
kera tinocyte cell line was received from Dr. N. E. Fusen ig (German Cancer 
Research Cente r, Heidelberg) (Boukamp el ai, 1988). The A375-SM, B16, 
and HaC aT cells we re routinely cultured in Eagle 's minimal essential 
Illedium sup plemented with 10'Vi, (v/v) feta l bovine semm . T he K1735-M2 
cell s were grown in Dulbecco's modified Eagle's medium supp lemented 
with 10% (v/v) fetal bovine serum, sodium pyruvate, nonessential amino 
acids, L-glutamjne, and twofo ld vitamin SOlution (Gibco) (Staroselsky el ai, 
199 1). 
Recombinant, Replication-Defective Adenoviruses The cons truc-
tion and ge neration of ad v serotype 5 containing thc HSV-tk gene under the 
control of Rous sa rcoma virus long terminal repeat has been described 
previously (Chen el ai, 1994). Adv carrying the J3-ga lactosidase gene (J3gal) 
serv ed as a contro l, the origina l stock of w hich was kindly provided by Dr. 
Michel Pcrricaudet (In st.ittlt Gustave Roussy, Villejuif Cedex, France) 
(Stratford-Pe rri caudet, 1992) . Viral titers were determincd by plaque assay 
on 293 cells and arc expressed in plaque forming units (pfu) (Graham and 
Prevec, 1991). 
Cell Culture Protocols In order t~ determine the ce ll line-specific 
sensitivi ty fo r "dv transduction, 1. 5 X '10' ce ll s were placed in culture dishes 
with a diameter of 3.5 cm. Twenty-four hours later attached ce ll s were 
tryps inized and counted in a hemocytomcte r. The subconAuent cul tures 
were rin sed once with scruI11-frec 111CdiUIl1, and {3gal-adv was added in a 
tota l volume of 1.5 ml of se rum-free medium per dish at multipli cities of 
infection (MO l) ranging from I 0 to 1000 pfu per attached cell. Three hours 
later 4 ml of fu ll y supplemented growth med ium (composition, see above) 
was added to each culture dish. At 24 h after onset of J3gal-adv exposure, 
cells were fixed in 2% paraformaldehyde/0.2% glu tara ldehyde (v/v) at 4°C 
for 10 min, and the numbcr of cells transduced was assessed by staining 
cu ltures with 5-bromo-4-chloro-3- indolyl-J3-D-galactopyrnnoside (X-gal) 
(Fisher Biotech, Fair Lawn, NJ) and ferro/ferric isothiocyaIH,te so lution 
essentially as described (MacGregor and Caskey, 1989). The percentage of 
transduced blue cell s was determined by coullting 10 separate microscopic 
fie lds in trip lica te. 
The combined effect of tk-adv and GCV (Cytovene, Syntex, Palo Alto , 
CAl was studied i" "il"" by seeding 5 X 10" A375-SM cell s per dish. After 
24 h the cultures were incubated with tk-adv ac a va rying MOl under the 
conditions for J3gal-adv described above . At 48 h after plating, the culture 
supernatant was replaced by 6 ml of g rowth m edium containing 4 ILg of 
GCV per ml or an appropriate volume of aqueous solvent (contro l) . Five 
days after seeding, the number of attached viable cell s was determined by 
trypan blue exclusion. This subtoxic concentration of 4 ILg of GCV per ml 
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treatment was determined by assessment of i" " ilrll GCV toxicity alone in 
the concentration range 2 to 10 ILg/ml. 
I" Vil/O Experiments Mclan0l113S were generated in a subcutaneous sire 
on the backs of6- to 8 -week-old athymic nude mice by injection of2.5 X 
10" A375-SM cells in 75 ILl of phosphate-buffered sa line under averrin 
anesthes ia. At 2.5 weeks, when melanomas typically reached a volume of 
abo ut 140 ± 20 mm3 (mean ± SD) as determined by three-dimensional 
micrometer-caliper measurement, tk-adv, J3ga l-adv, or Tris-buflered saline 
alone were injected intratul11orally . For this treatmen t anitnals were anes-
thesized with a ketal1'lille/xylazille combination. Amounts of 6.0 X 10" or 
1.2 X. 10') pfu of adv dissolved in 40-50 ILl of buffer were injected into the 
tumor center using a Hamilton syringe and a 30-gauge needle. To minimize 
leakage and to optinl izc the pcnctfcltiol1 of adv into the tllmor tissue . 
injections were performed slowly (1 ILI/') 5 s), and the needle was rcmo" cd 
after a delay of 20 min . The next day , virus- and buffer-injected animals 
were randomized with respect to initial tumor size. During the following .j 
or 6 d, GCV disso lved in iso tonic sodium chloride was applied intraperito-
nca lly at concentrations of60 or 40 mg/kg body weight twice daily. Control 
anima ls received intraperitoncalmock injections with sodium chloride. Five 
or 7 d after the intra tumoral adv injection the animals were sacrificed, the 
tUlnor vo)unlcs ca refully 111casllfcd. and [Ulnor vo llllne increase calculated 
with respect to the initial tumor volume at the day of adv i,~ection. 
Histochemic, Histopathologic, and Morphometric Analysis ofTu-
mor Tissue To demonstrate J3gal activity after ad v-mediated gene trans-
fer ill "illo, tumor material was fixed by a 1-h incubation at 4°C with 2% 
paraformaldehyde/0.2'X, glutara ldehyde, incubated overnight with X-gal 
(MacGregor and Caskey, 1989), sectioned, and li ghtly counterstained with 
nuclear fast red . For hi stologic eva luation, tumors were fixed in Carnoy's 
so lu tion (chloroform /acetic acid/ethanol, 3:1:6 v/v), embedded in paraffin. 
sectioned, und scaincd with hClllatoxylin und cosill. A cotnputerized 1110r-
phol1letric ana lysis with BIOQUANT softw:,re (BQ MEG IV; R &M 
Biometrics, Nashville) of the largest cross-sectiona l area of the residual 
tumor was performed by the point counting method because areas of 
necrotic tumor were not always contiguous. Briefly, at least 1600 predeter-
111incd points in the region of the tumor were assessed. FrOlll the total area 
of the tumor nodule (mm2 ) and the relative amount of necrosis (%), the 
resjdll ~:d ! v iable tUnlor area (1111112) was ca lculated for each tumor (Chen el nl. 
1995). 
Statistical Analysis Statistical probabilities were obtained by the Un-
paired t-test and the Wilcoxon-Malin-Whitney U-test. The level of 
significance was set to p < 0.05, unless otherwise sta ted . Multiple compar-
isons required Bonferroni's adjustment (Bonnekoh el ai, 1991). 
RESULTS AND DISCUSSION 
Transduction of Human and Murine Melanoma Cells by 
I3gal-adv It is well known that there is a broad range of 
susceptibi lity of different host cell types fo r adv infection, with some 
tropism for the ep ithe lial ce ll s of the respiratory tract (Kozarsky and 
Wilson, 1993). Data con cerning the susceptibility of melanoma 
cells for adenoviral infections are sparse, however, and relate 
mostly to murine studies (Zatloukal el ai, 1994; Bonnekoh er al 
1995) that employed adv as recombinant vec tors incorporating 
heterologous genes (BOIUlekoh ef ai, 1995) or as can'iers of nOI1-
covalently bound DNA comple xes (Zatloukal el ai, 1994) . 
In our previous report, we observed that B16 murine melanoma 
ce ll s appeared to require a higher adenovira l titer to achieve 100% 
transduction of ce ll s in (3ga l assays (Bonnekoh ef ai, 1995) , tlUl1 
other tumor ce ll s such as the C6 rat g lioma ce ll line (Chen et ai, 
1994) or the MCA-26 mouse colon ca rcinoma cell line (Chen et aI, 
1995). To assess w h ether this was a gen e ral feature of melanoma 
cell s (and therefore a potential problem), the infectivity of two 
murine (816 and K1735-M2) and one human m e lanoma (A375-
SM) cell lines was compared to a human nonmelanoma epidennal 
ce ll line, HaCaT. Cell s were infected at a varying MOl with 
{3gal-adv, and 24 h later the cell s were fixed and stained with X-gal, 
and the number of {3gal-expressing ce ll s was determined. The 
results shown in Fig 1 d e monstrate that, in the range from 10 to 
1000 pfu (3gal-adv/cell, a concentration-dependent increase in cell 
transduction was observed for all four lin es, with the highe t 
transduction rates of 80% being found for the human HaCaT 
keratinocyte ceU line and the human A375-SM melanoma cells 
(typical results are shown in Fig 2a), at the maximum MOl ofl000 
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Figure 1. I" lIitro transduction of cell lines by recombinant, repli-
I cation-defective f:lgal-adv. Hliman A375-SM melanoma ce lls, HaCaT keratinocy tes, toge ther with murine K1735-M 2 or B1 6 melanoma ce ll lines, were incubated with /3gal-adv at conccntrations indicated. Twenty-four 
I hour~ late r t?C nllmbcr oftransdllced cells was determined by X-gal stainjn.g (mplicate dI s hes, means :!: SD). Slglllficant dttferences for the adv trans-
ducibili ry of melanoma ce ll lincs were observed, with the A3 7S-SM being 
2.5- to 10- fold more sll sceptible to infection with adv. 
pfu /ceU (Fig 1) . At this MOl, the corresponding average trallSduc-
Don rate s for the murine K1735-M2 and B16 m elanoma ceU lines 
were 320/0 and 7'Xl, representing a 2.5- and l1-fold lower infec tivity, 
respectivel y , than fo r the human A3 75-SM melanoma cells. 
Although the mechani sms underlying ceUular adv transduction 
are ce rta inly complex, the injtial events of in tracellular entry of adv 
are th o ught to be particularly important for the transducibility of a 
given cell type (Smythe el ai , 1995) . Basically, it has been shown 
that the carboxyl-terminal kno b domain of the viral fibe r protein 
initially attaches to a specifi c, as ye t only partially characte rized , cell 
surfuce r ecepto r (Henry el ai , 1994; C rystal , 1995) . This event is 
known to b e followed by a specifi c interaction between Arg-Gl y-
Asp m o tifs o f the viral penton proteins and cellular vitronectin / 
fibron ectin-binding integrins a,, (33 and a,, (3s, triggerin g the endo-
somal upta k e of the virus parti cle (Greber et ai , 1993 ; Wickham el 
ai, 1993 ; M a thias el ai, 1994; Huang el ai, 1995) . The latter integrin 
seems to also fun ction in the subsequent release of the virus from 
the endosom e into the cyto plasm (Wickham el ai , 1994). In a recent 
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study primarily focusing on the diffe rential sensitivity of tho racic 
malignant tumor cells to adv tran sduction, a correlation w ith the 
cellular surface density of the a" integrin could be excluded 
(Smythe el ai , 1995). For m elan om a ce ll s, our findin g of a broad 
range of dive rgent adv susceptibilities awaits future careful charac-
terization o f the cascade o f criti ca l cellular even ts from vi ral entry 
to nuclear translocation, transcription , and subsequent translation 
processes. 
Tlus increased infectivity o f human versus murine m elano ma 
cells was also o bserved ill lIillo and bodes w ell for use of adv to trea t 
tumors in humans. R e latively large areas of intense X - gal stajJung 
w ere observed fo llowing in tra tumoral inj ection of established 
m elanomas with (3ga l-adv (Fig 2b). Injection speed proved to be 
criti ca l (1 {.Ll/15 s) for optimal transduction. In an attempt to assess 
the amount of adv required for transduction of tum ors at a given 
size, based on the general assumption that a tumo r m ass o f 1000 
mm" contains 109 cells (Fidle r, 1992) and the fac t that the average 
sizes o f the A37 5-SM m elanomas in separate experiments were 165 
and 122 mm 3 (see below) , the tumors w ere injected with 1.2 X 109 
and 6 .0 X 10~ pfu adv, respec ti ve ly, corresponding approximately 
to an infec tivity ratio of 7 and 5 pfu adv pe r tumor cell. Altho ugh 
these quantitative conside rations give some clues to compare the 
e ffects o bse rved ill lI i llO and ill lI itm, conside ration has to be given to 
the fac t that ill lI illO free access of the adv to all of the target cells is 
not achievable, resulting in an uneven tissue distl;bution of tum or 
ce ll transduction as observed in the histolog ic eva.luation of X - gal-
stam ed sections of (3gal-adv- treated m elanoma s (Fig 2b) . T lus 
observation may be somewhat o ffset, however, by the demonstra-
tion of a relatively strong bystander e ffect (see below). 
III Vitl'o GCV Cytotoxicity and Demonstration of a B y -
stander Effect in Human Melanoma Cells Pri o r to assess-
m ent of the effica cy of adenoviral-mediated HSV-tk gene de li ve l)' 
and GCV cytotoxicity ill lI il l'o, the sensiti vity of human A375-SM 
cells to GC V treatment alone was de termined. An tiproliferative 
e ffects of GCV on eukaryo tic cells are w ell documented in the 
literature , with an 1Dso ranging fro m 10 to 65 {.Lg/ml depending on 
the cell line and the assay condi tions (Faulds and H eel. 1990). Tlus 
influence of GC V on the pro ljfe ration of human A37 5-SM m ela-
nom a cells w as tes ted by incuba tion with concentration s of GCV 
be tween 2 and 10 {.Lg/ml for 3 d . Inhibition o f A375-SM cell 
proliferation was observed with GC V concentrations 2: 6 {.Lg / ml 
(dose toxicity curve not shown) ; the average number o f pro li fe r-
ating ceUs was redu ced by 2: 10'Yo. From the dose toxicity curve, a 
concentration of 4 {.Lg of GC V per ml w as ch osen as sub to xic and 
utilized fo r subsequent experiments. Tlus result show ed that human 
melanoma cells ill lIilm exhjbited greater sensitivity to GCV than 
murine B 16 ce lls, which exhibited no tox icity to GCV afte r 
incubation with 10 {.Lg/ ml for 6 d (Bonnekoh et ai , 1995 ) . 
The cyto toxic potential o f a combined tk-adv/GCV treatm ent 
on human A375-SM melanoma cells w as first 'lssessed ill II ill'O by a 
co-incubation experiment. After transduction by tk-adv at M O l 
ranging from 0.1 to 3000 pfu/cell , the cultures were kept wi th o r 
Figure 2. I,. ,,;11'0 and ill IIivo adv infectivity and histopathology of treated melanomas. a, detection of /3gal acti vity by X-ga l sta in ing in hllman 
A375-SM m elanoma cell s exposed to /3gnl-'ldv 24 h c<lrlicr at a MOl of 1000 pfll p CI' cell . Note a majority of positive bille cells (sra le bal', 3.5 J.l.m) . b. 
melanom a section stained with X-gal 2 d after intratumoral injection of flga l-adv demonstrates marked transduction of tll 111 or tissll e along the injection needle 
uact (sca le bal', 60 J.l.m) . c and rl, hematoxylin- and eosin-stained melanoma sections revealed that the /3g<ll/ganciclovir (GCV) treated control melanoma 
possessed only minor necrosis and inflammation (c), whereas the HSV-tk/GCV-treated tllmor exh.ibited ex tensive necros is of the tllmor ti sslle within 7 d (d) 
(<cale bar, 30 J.l.m) . 
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F igure 3. III ,,;1" 0 transduction ofhmnan A375-SM melanoma cells 
with tk-adv and treatment with GCV. Twenty-fo ll r hours after expo-
sure to tk-adv, cell s were clli tured fo r 3 d with and without GCV at a 
concentration of 4 I-'g/ml. Cell survival was assessed as compared to adv-
and GCV-frec cul ture condi tions, and significant cytotoxicity was observed 
at a MO l of 0.1 pfll tk-adv/ceU in the presence of GCV. Note also" 
signi fica nt cytotoxicity of adenovirus at a MO l ", 30 pfll /ce li. 
w ithou t GCV (4 JLg/ml) for 3 d , th en cell survival was determined . 
For the drug-free culture conditions, a signifIcant cy totoxic effect of 
tk- adv infec ti vity was o bserved beginn ing at an MO l of 0 .3 p fu/cell 
(Fig 3) and by an M O l of 30 pfu /ce ll the average ce ll surviva l 
dropped to 27'X,. Neverthe less, a clear effect of tk /GCV treatmen t 
was o bserved on A375-SM cells ill " itro. At an M O l as low as 0.1 , 
w hich exhibited no adv cytotoxici ty, onl y 32°/" of cells survived; 
this percen tage decreased to the background levels at an MO l of 1. 
Given an M O l of 0.1 pfu per cell , a maximum of l O'lI, o f ce ll s would 
theoreticaUy become infec ted, the reby clearl y indica tin g the pres-
ence of the so-called bystander effect (Freeman ct nl , 1993). 
To assess the str ength o f the bys tander efFect in an accompanying 
experiment , tk-adv-transdu ced and nontransdu ced A375-SM cells 
were mixed in a ratio o f 5 :95 and then cultured wi th 4 JLg GCV per 
ml fo r 3 d. Under these conditio l1S the sllrviva l rate dropped to 52% 
in compari son to nontransduced , GCV - treated control cultures. 
T his strong bystander effect fo r adv- tr ansduced human m elanoma 
cell cultures is in agreem en t wi th oth er assessm ents of the relative 
streng th of bystander effects, such as ill vilro fi ndings on murine 
K1 735- C19 cerebral m elanom a ce ll s, w here the retroviral trans-
duction of one ceJl wi th the tk gene led to th e destru cti on of ten 
neighboring ce ll s (W u et nl , 1994). 
III Vivo Growth Inhibition of Established Human Melano-
mas T he encourag ing increase in ill " itm e fri cacy o f the HSV -tkl 
GCV trea tment on human m elanoma ce lls with respect to B1 6 
murine m elanom a cells (Bonnekoh el nl, 1995) w as also borne out 
ill ,!ivo. N ot only was H SV-tk/GC V trea tm ent e ffi cacious, but 
human m elanomas also appeared to be relati ve ly sensitive to virus 
in fectio n alone . Two sets of experiments were p erfo rmed on large 
groups of mice bearing tumors o f diffe ring average sizes. 
In the fi rst experiment, at 18 d after subcutaneous cell injection 
th e melanom as typicaJly reached a volume of 165 ± 57 mm" and 
were treated wi th 1.2 X 10'> pfu tk- adv each , then evaluated afte r 
4-d administration of GCV at a dosage o f 60 mg/kg body weight 
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Figure 4. III ";"0 inhibition of growth of established hnman 
A375-SM melanoma by intra tumoral tk-adv/intraperitoneal GCV 
treatment. McI'lIlomas produced on the backs of nude mice (165 :':: :'7 
mmJ ) were slowly injected (1 1-'1115 s) with '1. 2 X 10" pfu of tk-adv. and 
GCV was given at 60 mg/ kg body weight, twice dail y, over the subsequent 
4 d. The fo llowing day tumors were evaluated wi th respect to the individu al 
tum o r vo lume ill crease (a) and hi sto mctrica l1 y w ith respect to the area of 
viable tlllTlOr remaining (II) . R.cs l.llts are expressed as means :':: SD. Statistical 
analys is was perform ed by the Wilcoxon-Mann-Whi tney U- test. Notc that 
a signi fica nt (50'%) growth reduction was observed in the tk/ GCV-rreated 
group, and "Iso that all effec t of adv ill fcction alone was observed. 
twice daily. W ith regard to the param eters o f tumor vo lume 
increase (Fig 4n) and res idual viable tumor area (111m2, Fig 4b) thi 
treatmen t regimen resulted in a highly significant effect in the group 
of animals trea ted with tk-adv /GCV compa red to the solvent 
con tro l g ro up (applicati on of bu ffe r intratumorally and NaCI 
in traperitoneally). T he tk-advIGC V-treated group exhibited only a 
1.2-fo ld increase in tum or volume compared to a 2.4-fold increase 
fo r the solven t con trol group. With respec t to residu al viable tumOr 
area, a stringent m orphom etric-computerized histologic an alysis 
(C hen l!l nl, 1995) demonstra ted that, no t only had the rklGCV 
trea tment hal ved the tumor grow th rate, but it also resu lted in a 
reduction of viable tumor area to an ave rage of 20% (19 nun2) of 
the total tumor area compared to th at of the solven t control (100% . 
93 mm2 ; Fig 4b) , i.e., only a fi fth of the treated melanoma 
remain ed viable. Given the degree of hete rogeneity observed on 
de livery of f3ga l-adv ill Jl iJlo (Fig 2b) , this aga in indicates the 
existence of a strong bystander e frec t (typica l histologic sections o f 
trea ted tumors are shown in Fig 2e,tI) . 
In this expel;ment, in volving a large number of animals, rwo 
othe r control treatm ent conditions were included : one group was 
treated with tk- adv intratumorall y alone, with out GCV trea011ent 
(NaCI intrape ritoneally) , and one group was mock-in fec ted with 
GCV only. Interestingly, a si gni~lcant effect (as compared to the 
solven t treatmen t con tro l g roup) w as o bserved for viable tumor 
area fo llowing tk-adv infection alone and in traperitoneal NaCI 
applica tion . H ere the histom etric eva lu ation gave a viable tumor 
area of 57 mm 2 (61 % of solvent con tro l, p = 0.0040; Fig 4b) and 
indica ted an increased ill Jl i Jlo sensitiv ity of hul11 an A375-SM cells to 
the cyto toxic effects o f adv infectivity, simil ar to that observed ill 
vitro (above) . N evertheless, w hen a statisti cal analysis to directly 
assess the e ffects of basic adenoviral infectivity to that o f tk/GCV 
treatment was perfo rmed by comparing the residual viable tumor 
area tk/ NaC I data (100%) to that of tk/ GC V treatment, a signifi-
cant effect o f the tk / GCV w as again o bserved. Consistent with th e 
presence of a strong bystander effec t, onl y 33% of the tk/ GCV-
treated tumors rem ained viabl e in comparison with the tk/ NaCI 
g ro up (p < 0.05) . 
T his e ffect of tk-adv infection alone prompted a careful analysi 
to con tras t the effects of basic adenoviral cy totoxicity to that of 
tk /GCV treatm ent of m elanoma . In this second experiment the 
tum ors were also injec ted w ith fewer vira l particles, 6.0 X 108 pfu 
of eithe r tk-adv o r f3ga l-adv, at 16 d after the subcutaneous tumor 
ce ll inoculation, when the melanomas reached a volume of 122 ± 
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I Figur~ 5. ~omparison of the efficacy .of tklG<?V treatment to 
infectIon vvlth adv alone. The growth mlubltory effect of tk-adv/GCV 
ueaOl1ent was compared directly to control /3gal-adv infection and GCV 
ueatment. The A37S-SM tumors were grown to a volume of122 ± 46 mmJ 
1 and then injected with 6.0 X 10" pfu adv. After treatment with GCV (40 mg 
per kg body weight. twice daily for 6 d). the tumor volume increase (a) and 
the remain.ing viable tumor area (II) were determined. Data are presented as 
means ± SD with statistica l analysis by the unpaired t-test. While an effect I of ad v alone was observed. the tk-adv/GCV treatment exhibited a signifi-
cantly increased efficacy. 
I 
46 nun3 . Subsequently, the animals received less GCV, 40 mg per 
, kg of body weight twice daily, and 7 d la ter the tumors were 
assessed. Under these optimized treatment conditions for both 
parameters, i.e., tumor volume increase and residual viab le tumor 
area, a direct comparison of tk-adv/GCV treatment versus {3gal-
adv/GCV gave highly signifi cant results (p = 0.0006 and p < 
0.0001, respectively), as shown in Fig Sa,b. The ave rage residual 
viable tun~or area was 28 mm 2 (36'X,) for the tk-adv/GCV condi-
I cion as compared to 78 111m2 (100%) with the ~gal-adv/GCV control (Fig Sb). Thus, a direct companson with a rIgorous I pgal-adv control clearly. demonstrated the thera~ellti~ efficacy of 
the tk gene transfer, wluch produced gene fUllctlon-lelated cyto-I tOxicity sign ificantly exceeding the adenoviral cytopathic effects. 
. These data a lso show that a significant effect on both growth and 
residual turnor area can be achieved at lower GCV doses that begin 
to approach clinically acceptable levels (Faulds and Heel, 1990). 
With respect to our observation of basic adv cytotox.icity in the 
' absence of tk /GCV under the chosen conditions of locally high 
virus concentrations in the A375-SM melanomas , a previous report 
showed that transduction of cultmed primary human airway epi-
thelial cells w ith an E1,E3-deleted CMV-IacZ-adv vector resulted 
in increased apoptotic cell death and lowered recruitment of cells 
into S phase (Teramoto et aI, 1995). It should be noted that these 
eifects could be eliminated by ultraviolet inactivation of the vector, 
indicating that viral gene expression is involved in the slowing of 
cell growth. 
Additionally, our histologic analysis revea led that the tk-advl 
GCV-induced necrosis was always related to the injected tumor 
area. An injury of peritumoral normal tissue, e .g., derm al and 
subcutaneous connective tissue including blood vessels and the 
overlying epidermis, was not observed. An inflammatory infiltrate 
was virtually absent in untreated control tumors; however, some 
parts of the peripheral surviving tumor areas showed sparse infil-
trates predominantly of neutrophils at day 7 after the onset of the 
treatment \Nith tk- or {3gal-adv/GCV, respectively. T hjs finding 
( reflects th~ athYI:,ic nature of the n~lde mouse model used in tlus 
I study, while typ ica lly lymphocytic mfiltrates have been reported 
after adv application in immune-competent animal models (Yang el 
al, 1995) . 
Thjs study demonstrates that the growth of A37S-SM melanoma 
in nude mice was sign ifi cantly reduced by an adv-mediated intra-
wmoral transfer of tk followed by GCV treatment, thereby pro-
viding evidence that human melanoma cells can be subjected to an 
efficient gene deliv ery ;11 s;11I mediated by adv. Indeed, our data 
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suggest that human A375-SM melanoma cells arc more sensitive to 
the cytotoxic effects of tk-adv/ GCV and the bystander effect than 
previously observed with murine B16 m elanomas (Bonnekoh el aI, 
1995 ). This conclusion is based on both the observed increase in 
sensitivity of human m elanoma cells to tk /GCV treatment ;11 II;lro 
and the observation that even given an effect of adv infectivity 
alone, the residual viab le tumor area of treated hunlaJl melanomas 
was reduced to one-fifth that of untreated controls. Thus, for 
treatment of melanoma, it may be that tile efficacy observed in 
model systems with murine tumors lInderrepresents what may be 
achievable for humans. 
Given this encouraging observation, our ongoing work, I w luch 
employs murine immun e-competent, syngeneic melanoma models , 
has begun to explore the conditions under wluch the adv-mediated 
direct application of cyto1cines into a localized tumor compartment 
evokes optimum systemic anti-tumor protection (Rankin, 1995) . 
This is clearly necessary, because a simple suicide gene approach 
cannot treat disseminated metastases; i.e . . only loca.l efficacy at the 
application site can be expected despite the actions of the bystander 
effect coupled to an increased sensitivity of human mela.noma cells . 
As adv-mediated gene transfer has already been employed clinically 
for the treatment of cystic fibrosis (Crystal, 1995), successful 
immunotherapy or combination gene therapy identified in such 
animal model systems may be readily transferable to the clinical 
field of adjuvant melanoma treatment. 
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